SUPERNUS PHARMACEUTICALS, INC.
SUPNNasdaq
$48.04
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↑ +43.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.8B
Enterprise Value
$2.6B
P/E
—
P/S
3.6
P/B
2.6
EV/EBITDA
69.9
PEG
—
FCF Yield
3.0%
Dividend Yield
—
Revenue (TTM)
$776.8M
Net Income (TTM)
-$29.1M
Free Cash Flow (TTM)
$82.2M
Gross Margin
—
Operating Margin
-7.8%
Net Margin
-3.7%
ROE
-2.7%
ROIC
-5.3%
Debt / Equity
—
Net Cash
$184.9M
Return 1Y
+43.0%
Company profile
Supernus Pharmaceuticals, Inc. focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the. treatment of epilepsy, as well as for the prophylaxis of migraine headache. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.
- CEO
- Jack A. Khattar
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 580
- Headquarters
- Maryland
- Website
- supernus.com
Management & directors
- Bhatt Padmanabh P.Sr. VP of IP, CSO
- Khattar Jack A.President, CEO
- Horich William ToddSVP, Commercial Operations
- Mottola FrankSVP, Chief Tech. Ops. Officer
- Dec Timothy CSenior Vice-President & CFO
- Rubin JonathanSVP, Chief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
SUPN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$207.7M↑ +38.6%
Diluted EPS-$0.04↓ -81.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $520.4M | $579.8M | $667.2M | $607.5M | $661.8M | $719.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $173.7M | $86.0M | $46.1M | -$5.3M | $81.7M | -$62.3M |
| Net income | $127.0M | $53.4M | $60.7M | $1.3M | $73.9M | -$38.6M |
| Diluted EPS | $2.36 | $0.98 | $1.04 | $0.02 | $1.32 | -$0.68 |
| Operating cash flow | $138.4M | $127.1M | $116.8M | $111.1M | $172.0M | $47.3M |
| Free cash flow | $134.9M | — | $116.4M | $110.5M | $171.2M | $46.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 33.4% | 14.8% | 6.9% | -0.9% | 12.3% | -8.7% |
| Net margin | 24.4% | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $168.3M | $175.7M | $174.2M | $149.8M | $165.5M | $192.1M | $211.6M | $207.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $22.6M | $40.8M | $21.4M | -$10.3M | $12.1M | -$60.2M | -$3.9M | -$8.3M |
| Net income | $19.9M | $38.5M | $15.4M | -$11.8M | $22.5M | -$45.1M | -$4.2M | -$2.3M |
| Diluted EPS | $0.36 | $0.69 | $0.27 | -$0.21 | $0.40 | -$0.80 | -$0.07 | -$0.04 |
| Operating cash flow | $35.6M | $53.5M | $44.4M | $30.6M | $58.5M | -$61.7M | $19.9M | $66.5M |
| Free cash flow | $35.6M | $53.3M | $44.2M | $30.3M | $58.1M | -$61.8M | $19.4M | $66.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 13.4% | 23.2% | 12.3% | -6.8% | 7.3% | -31.4% | -1.9% | -4.0% |
| Net margin | 11.8% | 21.9% | 8.8% | -7.9% | 13.6% | -23.5% | -2.0% | -1.1% |
Company news
Jul 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-18 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Sale | 6,838 | $49.55 | $338,822.90 | filing |
| 2026-03-18 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Option exercise | 7,250 | $39.40 | $285,650.00 | filing |
| 2026-03-18 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Sale | 412 | $50.48 | $20,797.76 | filing |
| 2026-03-17 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Sale | 27,710 | $49.95 | $1.4M | filing |
| 2026-03-17 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Sale | 22,290 | $50.73 | $1.1M | filing |
| 2026-03-17 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Option exercise | 22,750 | $39.40 | $896,350.00 | filing |
| 2026-03-17 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Option exercise | 15,000 | $38.60 | $579,000.00 | filing |
| 2026-03-17 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Option exercise | 12,250 | $36.75 | $450,187.50 | filing |
| 2026-03-16 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Sale | 34,114 | $50.18 | $1.7M | filing |
| 2026-03-16 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Option exercise | 22,750 | $36.75 | $836,062.50 | filing |
| 2026-03-16 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Sale | 15,886 | $50.49 | $802,084.14 | filing |
| 2026-03-16 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Option exercise | 18,000 | $32.20 | $579,600.00 | filing |
| 2026-03-16 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Option exercise | 5,000 | $27.94 | $139,700.00 | filing |
| 2026-03-16 | Bhatt Padmanabh P.· Sr. VP of IP, CSO | Option exercise | 4,250 | $29.61 | $125,842.50 | filing |
| 2026-03-13 | Khattar Jack A.· President, CEO | Sale | 24,138 | $50.09 | $1.2M | filing |
| 2026-03-13 | Khattar Jack A.· President, CEO | Sale | 10,742 | $51.00 | $547,842.00 | filing |
| 2026-03-13 | Khattar Jack A.· President, CEO | Sale | 120 | $51.75 | $6,210.00 | filing |
| 2026-03-13 | Khattar Jack A.· President, CEO | J | 12,500 | — | — | filing |
| 2026-03-13 | Khattar Jack A.· President, CEO | J | 12,500 | — | — | filing |
| 2026-03-12 | Hudson Frederick M. | Sale | 5,369 | $50.61 | $271,725.09 | filing |
| 2026-03-10 | Horich William Todd· SVP, Commercial Operations | Sale | 4,439 | $55.00 | $244,145.00 | filing |
| 2026-03-09 | Horich William Todd· SVP, Commercial Operations | Sale | 4,438 | $54.00 | $239,652.00 | filing |
| 2026-03-09 | Mottola Frank· SVP, Chief Tech. Ops. Officer | Sale | 1,623 | $53.65 | $87,073.95 | filing |
| 2026-03-06 | Khattar Jack A.· President, CEO | Tax withholding | 16,574 | $54.73 | $907,095.02 | filing |
| 2026-03-06 | GEMAYEL GEORGES | Sale | 8,787 | $53.00 | $465,711.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.